165 related articles for article (PubMed ID: 26444996)
1. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Papastergiou V; Thalassinos E; Mantzoukis K; Rodriguez-Peralvarez M; O'Brien J; Noel-Storr A; Papatheodoridis GV; Davidson B; Burroughs AK
J Viral Hepat; 2016 Feb; 23(2):139-49. PubMed ID: 26444996
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.
Tsochatzis EA; Crossan C; Longworth L; Gurusamy K; Rodriguez-Peralvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Noel-Storr A; Davidson B; Burroughs AK
Hepatology; 2014 Sep; 60(3):832-43. PubMed ID: 25043847
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
Stevenson M; Lloyd-Jones M; Morgan MY; Wong R
Health Technol Assess; 2012; 16(4):1-174. PubMed ID: 22333291
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
7. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
8. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
Liu Y; Zhang H; Zhang L; Zou X; Ling L
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012839
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
Wong JB; Bennett WG; Koff RS; Pauker SG
JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
[TBL] [Abstract][Full Text] [Related]
15. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Tian F; Houle SKD; Alsabbagh MW; Wong WWL
Pharmacoeconomics; 2020 Feb; 38(2):181-192. PubMed ID: 31691902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
